Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay

[1]  P. Nuciforo,et al.  HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. , 2017, The Lancet. Oncology.

[2]  J Cuzick,et al.  Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  C. Perou,et al.  Defining breast cancer intrinsic subtypes by quantitative receptor expression. , 2015, The oncologist.

[4]  Jong-Hyeon Jeong,et al.  Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Perou,et al.  Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer , 2014, Journal of the National Cancer Institute.

[6]  A. Wolff,et al.  Treatment of HER2-positive breast cancer. , 2014, Breast.

[7]  Anton Belousov,et al.  Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study , 2014, Clinical Cancer Research.

[8]  M. Dowsett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Goldstein,et al.  Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[12]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[13]  M. Press,et al.  Characterization of HER2 status by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). , 2014, Methods in molecular biology.

[14]  P. Fitzgibbons,et al.  Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer , 2022 .